Business Standard
Thursday, Feb 16, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Glenmark receives US FDA nod for Ezetimibe
Press Trust Of India / New Delhi Apr 27, 2009, 15:28 IST

Drug firm Glenmark Generics Ltd today said it has received tentative approval from the US Food and Drug Administration (FDA) for the generic version of cholesterol lowering drug Ezetimibe, sold under the brand name 'Zetia' in 10 mg strength.      

Glenmark has got the tentative approval for the generic version of Schering Plough and MSP Singapore Company LLC's anti-cholesterol compound Ezetimibe, which has received sales of 1.5 billion dollars in 2008, the company said in a statement.     

The company believes that it is first to file status on Ezetimibe tablets and thereby it also has a potential of getting marketing exclusivity of 180 days in the US.      

However, the company said, product launch is dependent upon receipt of final approval from the FDA and is also dependent on the outcome of litigation currently pending in the US district court of New Jersey.      

Glenmark had filed its Abbreviated New Drug Application with FDA seeking regulatory approval to market a generic version of Ezetimibe in 2006.      

Glenmark Generics is a US-based subsidiary of Mumbai head quartered Glenmark Pharmaceuticals Ltd.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end lower on profit booking
- We don't want player retention policy in future IPL: Roy
- ONGC may invoke force majeure clause for 2 KG blocks
- SC verdict paves way for NTPC to place Rs 16,000 cr orders
- Aadhar cards to verify LPG, phone connections: Nilekani
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Medium-sized businesses are the engines of a smarter planet.
- Save over Rs.3000 with IndianOil Citibank Card
- We live for our family. have you secured them?
- India's No. 1 Property Site. Click here to know more..
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Get 5% cashback on telephone bills with Citi
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Be part of it The World's Largest Aircraft.
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Office 365 for professionals and small businesses.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
- Health is Wealth..... Insurance + Savings... Know More...
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- Leela parts ways with Kempinski
- Kanika Datta: The importance of being SRK
- Nestle: Food for thought
- Tailor-made but not good enough
- Star-studded jury honours corporate excellence
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us